GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Cyclically Adjusted Book per Share

Lineage Cell Therapeutics (XTAE:LCTX) Cyclically Adjusted Book per Share : ₪2.93 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lineage Cell Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was ₪1.426. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₪2.93 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Lineage Cell Therapeutics's average Cyclically Adjusted Book Growth Rate was 1.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lineage Cell Therapeutics was 41.30% per year. The lowest was -40.70% per year. And the median was 10.15% per year.

As of today (2024-05-17), Lineage Cell Therapeutics's current stock price is ₪3.931. Lineage Cell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₪2.93. Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio of today is 1.34.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lineage Cell Therapeutics was 29.14. The lowest was 0.84. And the median was 3.74.


Lineage Cell Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Lineage Cell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Cyclically Adjusted Book per Share Chart

Lineage Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.26 2.29 2.37 2.68 2.94

Lineage Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.94 3.28 2.94 2.93

Competitive Comparison of Lineage Cell Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio falls into.



Lineage Cell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lineage Cell Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.426/131.7762*131.7762
=1.426

Current CPI (Mar. 2024) = 131.7762.

Lineage Cell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.801 100.560 1.050
201409 0.407 100.428 0.534
201412 1.566 99.070 2.083
201503 1.080 99.621 1.429
201506 0.639 100.684 0.836
201509 0.591 100.392 0.776
201512 1.061 99.792 1.401
201603 0.446 100.470 0.585
201606 3.135 101.688 4.063
201609 4.318 101.861 5.586
201612 4.265 101.863 5.517
201703 6.283 102.862 8.049
201706 5.905 103.349 7.529
201709 6.365 104.136 8.054
201712 4.766 104.011 6.038
201803 2.929 105.290 3.666
201806 2.959 106.317 3.668
201809 5.013 106.507 6.202
201812 2.744 105.998 3.411
201903 4.052 107.251 4.979
201906 3.313 108.070 4.040
201909 2.907 108.329 3.536
201912 2.803 108.420 3.407
202003 2.642 108.902 3.197
202006 2.467 108.767 2.989
202009 2.262 109.815 2.714
202012 2.336 109.897 2.801
202103 2.699 111.754 3.183
202106 2.775 114.631 3.190
202109 2.664 115.734 3.033
202112 2.023 117.630 2.266
202203 1.896 121.301 2.060
202206 1.814 125.017 1.912
202209 1.727 125.227 1.817
202212 1.603 125.222 1.687
202303 1.539 127.348 1.593
202306 1.549 128.729 1.586
202309 1.447 129.860 1.468
202312 1.347 129.419 1.372
202403 1.426 131.776 1.426

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Lineage Cell Therapeutics  (XTAE:LCTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lineage Cell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.931/2.93
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lineage Cell Therapeutics was 29.14. The lowest was 0.84. And the median was 3.74.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lineage Cell Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics (XTAE:LCTX) Headlines

From GuruFocus